imetelstat,luspatercept,epoetin alfa
geron corporation,bms
['commands', 'lusp', 'commands trial', 'commands,(-recommands)', 'mds', 'imerge trial']
eagerly awaiting upcoming presentations on 2 novel therapies in transfusion-dependent mds: the commands trial of luspatercept upfront vs epo, and the imerge trial of imetelstat in epo-refractory lower-risk mds. there remain many unmet needs in this area clinically #mdssm #asco23
Patient experience & cancer outcomes researcher | Leukemia & palliative care doc | Chief PX and Safety Officer @DukeCancer | HeForShe. Tweets mine.